title: Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis.
authors.affiliation: Department of Dermatology, University Hospital of Saint-Etienne, 42055 Saint Etienne Cedex 2, France. elisacinotti@gmail.com.
authors.forename: E
authors.initials: E
authors.lastname: Cinotti
authors.forename: B
authors.initials: B
authors.lastname: Labeille
authors.forename: J L
authors.initials: JL
authors.lastname: Perrot
authors.forename: B
authors.initials: B
authors.lastname: Pallot-Prades
authors.forename: F
authors.initials: F
authors.lastname: Cambazard
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D000068582:Certolizumab Pegol; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D007166:Immunosuppressive Agents; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol